Glenn Tillotson is a consultant microbiologist working the pharmaceutical industry. He provides support for both medical affairs and commercialization programs for companies, most notably in the infectious disease area. He has had a number of senior roles in the pharmaceutical industry and was an integral member of the Cipro and Avelox teams while at Bayer. Since then he has been involved in several Clostridioides difficile programs. He is Editor in Chief of Expert Opinion in Anti-Infective Therapy journal.
In These COVID 19 Times, Can We Reduce Hospitalizations Due to Skin Infections?January 13th 2022
Shortages of health care workers and an increase in COVID-19 cases has put a severe strain on the health care system. Thus, the opportunity to reduce the hospitalizations for other conditions and expand outpatient treatment opportunities should be welcomed.